These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 37509227)

  • 1. Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).
    Nardin C; Hennemann A; Diallo K; Funck-Brentano E; Puzenat E; Heidelberger V; Jeudy G; Samimi M; Lesage C; Boussemart L; Peuvrel L; Rouanet J; Brunet-Possenti F; Gerard E; Seris A; Jouary T; Saint-Jean M; Puyraveau M; Saiag P; Aubin F
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
    Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
    Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma.
    Scheiner B; Roessler D; Phen S; Lim M; Pomej K; Pressiani T; Cammarota A; Fründt TW; von Felden J; Schulze K; Himmelsbach V; Finkelmeier F; Deibel A; Siebenhüner AR; Shmanko K; Radu P; Schwacha-Eipper B; Ebert MP; Teufel A; Djanani A; Hucke F; Balcar L; Philipp AB; Hsiehchen D; Venerito M; Sinner F; Trauner M; D'Alessio A; Fulgenzi CAM; Pinato DJ; Peck-Radosavljevic M; Dufour JF; Weinmann A; Kremer AE; Singal AG; De Toni EN; Rimassa L; Pinter M
    JHEP Rep; 2023 Jan; 5(1):100620. PubMed ID: 36578451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
    Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
    Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.
    Vauchier C; Auclin E; Barthélémy P; Carril-Ajuria L; Ryckewaert T; Borchiellini D; Castel-Ajgal Z; Bennamoun M; Campedel L; Thiery-Vuillemin A; Coquan E; Crouzet L; Berdah JF; Chevreau C; Ratta R; Fléchon A; Lefort F; Albiges L; Gross-Goupil M; Vano YA; Thibault C; Oudard S
    J Oncol; 2022; 2022():3449660. PubMed ID: 35222642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies.
    Kim M; Chang CS; Choi MC; Lee JW; Park H; Joo WD
    Yonsei Med J; 2023 Oct; 64(10):587-592. PubMed ID: 37727917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma.
    Shah P; Punekar SR; Pavlick AC
    Melanoma Res; 2021 Jun; 31(3):242-248. PubMed ID: 33741813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma.
    Jin Z; Cao Y; Lu Z; Liu C; Shen L
    Int Immunopharmacol; 2024 Aug; 137():112364. PubMed ID: 38865752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study.
    Hong Y; Liu J; Lu P; Chang Z; Zhang G; Ma X; Liang W; Tian Y; Xia J; Cao H; Huang J
    Oncologist; 2024 Sep; ():. PubMed ID: 39303674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.
    Xu Z; Hao X; Yang K; Wang Q; Wang J; Lin L; Teng F; Li J; Xing P
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3081-3089. PubMed ID: 34982222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study.
    Yan X; Zhao L; Wu F; Shen B; Zhou G; Feng J; Yue C; Zhu J; Yu S
    J Thorac Dis; 2024 Mar; 16(3):1787-1803. PubMed ID: 38617775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study.
    Yang J; Zeng R; Zhou J; Luo L; Lyu M; Liu F; Sun X; Zhou L; Wang X; Bao Z; Chen W; Dumoulin DW; Gao B; Xiang Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1038-1050. PubMed ID: 35832441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients.
    Zaremba A; Eggermont AMM; Robert C; Dummer R; Ugurel S; Livingstone E; Ascierto PA; Long GV; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 Sep; 155():268-280. PubMed ID: 34392069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study.
    Lin X; Deng H; Chu T; Chen L; Yang Y; Qiu G; Xie X; Qin Y; Liu M; Xie Z; Ouyang M; Li S; Song Y; Petrella F; Jakopovic M; Tsoukalas N; Solli P; Goto T; Saito Y; Zhou C
    Transl Lung Cancer Res; 2022 Nov; 11(11):2289-2305. PubMed ID: 36519018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).
    Ito S; Asahina H; Honjo O; Tanaka H; Honda R; Oizumi S; Nakamura K; Takamura K; Hommura F; Kawai Y; Ito K; Sukoh N; Yokoo K; Morita R; Harada T; Takashina T; Goda T; Dosaka-Akita H; Isobe H;
    Lung Cancer; 2021 Jun; 156():12-19. PubMed ID: 33872943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
    Leiter U; Loquai C; Reinhardt L; Rafei-Shamsabadi D; Gutzmer R; Kaehler K; Heinzerling L; Hassel JC; Glutsch V; Sirokay J; Schlecht N; Rübben A; Gambichler T; Schatton K; Pfoehler C; Franklin C; Terheyden P; Haferkamp S; Mohr P; Bischof L; Livingstone E; Zimmer L; Weichenthal M; Schadendorf D; Meiwes A; Keim U; Garbe C; Becker JC; Ugurel S
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.